EMA grants marketing authorization to Alkindi for treatment of primary adrenal insufficiency


eMediNexus    19 December 2017

The European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a paediatric-use marketing authorisation for Alkindi (hydrocortisone) for the treatment of primary adrenal insufficiency, a rare hormonal disorder, in infants, children and adolescents.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.